On the whole, the effects of mTOR overactivity in TSC patients lead to a multi-system phenotype that includes widespread hamartoma growth, high prevalence of epilepsy and, in up to 50% of the patients, ASD (Kingswood et al., 2017; McDonald et al., 2017). The gene discussed is MTOR; the disease is tuberous sclerosis.